Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by enhancing anti-tumor immune responses, yet their use can lead to immune-related adverse events (irAE), including neurological complications. Despite their clinical relevance, predictive biomarkers for irAE remain scarce, and ea...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2025-12-01
|
| coleção: | OncoImmunology |
| Assuntos: | |
| Acesso em linha: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2547271 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
